Onyx (, which develops cancer drugs and treatments, said Monday that Amgen's takeover bid of $120 a share undervalued the company. Onyx stock closed Friday at $86.82. )
"We are actively exploring the potential to combine Onyx with another company as an option to create additional value for Onyx shareholders," said Onyx CEO N. Anthony Coles.
Shares of Onyx rose more than 6% last week on news of Amgen's offer. Overall, the stock has increased nearly 36% since last year.
Amgen (Fortune 500) is a major player in biopharmaceuticals, and manufactures drugs for many conditions, including ones that counteract the effects of cancer treatments. ,
|Regulators pave way for Internet "fast lane" with net neutrality rules|
|Apple shares soar on increased buyback|
|What stumps Warren Buffett? Minimum wage|
|Analysts offer no apologies for missing Apple's Q2 2014 earnings beat|
|Premarkets: Buoyed by Apple, Facebook earnings|